ZIP12 Antibody for Hypoxia Diseases, Pulmonary Hypertension, Cancer
Summary
The USPTO published patent application US20260109761A1 for ZIP12 antibodies covering compositions, pharmaceutical formulations, kits, and methods for treating and diagnosing hypoxia-related diseases including pulmonary hypertension and cancer. The application, filed on September 24, 2025 under application number 19339013, names inventors Stephanie HOPLEY, Martin WILKINS, and Lan ZHAO. CPC classifications include C07K 16/28 and A61P 9/12, indicating antibody-based therapeutic compositions for cardiovascular indications.
“The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
The USPTO published a new patent application for ZIP12 antibodies as an A1 publication (application under examination). The application covers antibody compositions, pharmaceutical compositions, kits, and methods of making and using the antibodies for therapy and diagnosis of hypoxia-related diseases such as pulmonary hypertension and cancer.
Pharmaceutical and biotechnology companies developing antibody therapeutics for hypoxia-related diseases, pulmonary hypertension, or oncology should review the application claims to assess potential freedom-to-operate considerations or licensing opportunities.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ZIP12 ANTIBODY
Application US20260109761A1 Kind: A1 Apr 23, 2026
Inventors
Stephanie HOPLEY, Martin WILKINS, Lan ZHAO
Abstract
The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.
CPC Classifications
C07K 16/28 A61P 9/12 A61K 2039/505 C07K 2317/33 C07K 2317/77 C07K 2317/92
Filing Date
2025-09-24
Application No.
19339013
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.